Lexeo CEO R. Nolan Townsend

Lex­eo Ther­a­peu­tics and Abi­vax seek Nas­daq list­ings in shrink­ing pre-Thanks­giv­ing win­dow for biotech IPOs

The gene ther­a­py start­up Lex­eo Ther­a­peu­tics and in­flam­ma­to­ry dis­ease biotech Abi­vax filed pa­per­work to go pub­lic Fri­day af­ter­noon, as the pre-Thanks­giv­ing IPO win­dow shrinks and a gov­ern­ment shut­down looms.

New York-based Lex­eo and Paris-based Abi­vax would join about a dozen oth­er drug de­vel­op­ers in go­ing pub­lic this year, aim­ing to trade on the Nas­daq un­der the tick­ers $LX­EO and $AB­VX, re­spec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.